International Journal of STD & AIDS最新文献_第6页

A rare case report of hemophagocytic lymphohistiocytosis secondary to pure eythroid leukemia in a person living with HIV. 艾滋病病毒感染者继发于纯合子白血病的嗜血细胞淋巴组织细胞增多症的罕见病例报告。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-11-01 Epub Date: 2024-08-22 DOI: 10.1177/09564624241273811

Varsha Luthra, Ankita Garg, Tarun Chaudhary, Anita Tahlan, Monica Gupta

引用次数: 0

Assessing novel partner antimicrobials to protect ceftriaxone against gonococcal resistance: An in vitro evaluation. 评估新型伙伴抗菌剂，以保护头孢曲松免受淋球菌耐药性的影响：体外评估。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-11-01 Epub Date: 2024-09-03 DOI: 10.1177/09564624241280082

Saïd Abdellati, Zina Gestels, Yuliia Baranchyk, Tessa de Block, Dorien Van Den Bossche, Irith De Baetselier, Sheeba Santhini Manoharan-Basil, Chris Kenyon

{"title":"Assessing novel partner antimicrobials to protect ceftriaxone against gonococcal resistance: An in vitro evaluation.","authors":"Saïd Abdellati, Zina Gestels, Yuliia Baranchyk, Tessa de Block, Dorien Van Den Bossche, Irith De Baetselier, Sheeba Santhini Manoharan-Basil, Chris Kenyon","doi":"10.1177/09564624241280082","DOIUrl":"10.1177/09564624241280082","url":null,"abstract":"Background: The emergence of ceftriaxone-resistant Neisseria gonorrhoeae poses a significant threat to existing treatment regimens. Our study aimed to assess the efficacy of antimicrobials that could be combined with ceftriaxone to reduce the probability of ceftriaxone resistance emerging and spreading in N. gonorrhoeae.Methods and results: Broth microdilution was used to determine the minimal inhibitory concentrations (MICs) for a panel of ceftriaxone-resistant (WHO X, Y, Z) and ceftriaxone-susceptible (WHO L, N, P) N. gonorrhoeae WHO reference strains for the following antimicrobials: ceftriaxone, doxycycline, azithromycin, zoliflodacin, fosfomycin, pristinamycin, ramoplanin, gentamicin and NAI-107. The MICs for zoliflodacin and pristinamycin for all strains were lower than or equal to the available breakpoints. A checkerboard assay was used to determine the drug-drug combination effect, which showed either an indifferent or an additive effect for all the combinations tested with ceftriaxone.Conclusions: The low MICs of zoliflodacin and pristinamycin for the three ceftriaxone-resistant strains suggest that these antimicrobials could be used as partner drugs with ceftriaxone to reduce the probability of ceftriaxone resistance spreading in areas with a high prevalence of ceftriaxone resistance.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"1042-1049"},"PeriodicalIF":1.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IUSTI Europe position statement on use of DoxyPEP: June 2024. 欧洲 IUSTI 关于使用 DoxyPEP 的立场声明：2024 年 6 月。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-11-01 Epub Date: 2024-08-21 DOI: 10.1177/09564624241273801

Jackie Sherrard, Deniz Gokengin, Andrew Winter, Michael Marks, Magnus Unemo, Jorgen S Jensen, Marco Cusini, Otilia Mårdh

引用次数: 0

Effectiveness and safety of tildrakizumab in individuals with HIV and psoriasis: A case series. 替雷珠单抗对艾滋病病毒感染者和银屑病患者的有效性和安全性：病例系列。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-11-01 Epub Date: 2024-09-03 DOI: 10.1177/09564624241279489

Jonathan Krygier, Bertrand Richert

引用次数: 0

Genital-oral transmission of Candida lusitaniae. 卢西塔尼亚念珠菌的生殖器-口腔传播。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-10-29 DOI: 10.1177/09564624241296582

Stefano Veraldi, Paolo Bortoluzzi, Francesca Germiniasi, Anna Grancini

引用次数: 0

HIV retesting among people living with HIV in Lesotho in 2022. 2022 年莱索托艾滋病毒感染者的艾滋病毒再检测。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-10-22 DOI: 10.1177/09564624241289984

Spencer D Pogue, Suzue Saito, Mphotleng Tlhomola, Christine A West, Fred Asiimwe, Puleng Ramphalla, Eugenie Poirot, Claire Steiner, Abigail R Greenleaf

{"title":"HIV retesting among people living with HIV in Lesotho in 2022.","authors":"Spencer D Pogue, Suzue Saito, Mphotleng Tlhomola, Christine A West, Fred Asiimwe, Puleng Ramphalla, Eugenie Poirot, Claire Steiner, Abigail R Greenleaf","doi":"10.1177/09564624241289984","DOIUrl":"https://doi.org/10.1177/09564624241289984","url":null,"abstract":"Background: Despite widespread HIV testing in sub-Saharan Africa, regular testing among at-risk populations is crucial for effective prevention. However, reports increasingly indicate retesting among people living with HIV (PLHIV), a group that would not require additional testing since they would already have received a confirmed diagnosis. We describe the demographic characteristics of PLHIV retesters in Lesotho, report the average number of HIV tests post-diagnosis among PLHIV, and share motivations for retesting.Methods: In August 2022, a nationally representative cohort in Lesotho participated in a cell phone survey about their HIV status and testing history. Study participants were recruited from a face-to-face survey conducted in 2020, Lesotho Population Based HIV Impact Assessment survey.Results: Of the 1523 participants called, 1111 participants responded (72.9%) and 266 reported living with HIV. We found 18.8% of people living with HIV (PLHIV) reported retesting at least once for HIV, and 58% of PLHIV who reported retesting were likely or very likely to retest for HIV in the coming year. The main reason PLHIV reported retesting was because a health care worker offered the test (61.7%) followed by self-initiated testing to confirm their status (29.1%). Among male PLHIV who had a history of retesting, 92.0% were very likely or likely to retest, compared to only 30.6% of female PLHIV.Conclusion: We found almost a fifth of PLHIV in Lesotho reported a history of retesting for HIV, and 58% of PLHIV were likely or very likely to retest for HIV in the coming year. Educating providers and men living with HIV could reduce retesting among PLHIV.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624241289984"},"PeriodicalIF":1.4,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

British Association of Sexual Health and HIV UK national guideline for the management of anogenital herpes, 2024. 英国性健康和艾滋病协会《2024 年英国肛门疱疹管理国家指南》。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-10-07 DOI: 10.1177/09564624241282396

Raj Patel, John Green, Benjamin Moran, Emily Clarke, Kanchana Seneviratne, Ceri Evans, Felicity Young, Marian Nicholson, Emanuela Pelosi, Margaret Kingston, Elizabeth Foley

引用次数: 0

Case series of two persons living with HIV with detectable viral loads initiated then suppressed on cabotegravir/rilpivirine with lenacapavir. 两名检测到病毒载量的艾滋病病毒感染者的病例系列，他们开始使用卡博特拉韦/利匹韦林联合来那卡韦治疗，随后病情得到抑制。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-10-03 DOI: 10.1177/09564624241288293

Kimberly L O'Neil, Patrick R Ching, Robert T Higginson, Patricia Pecora Fulco

{"title":"Case series of two persons living with HIV with detectable viral loads initiated then suppressed on cabotegravir/rilpivirine with lenacapavir.","authors":"Kimberly L O'Neil, Patrick R Ching, Robert T Higginson, Patricia Pecora Fulco","doi":"10.1177/09564624241288293","DOIUrl":"https://doi.org/10.1177/09564624241288293","url":null,"abstract":"Long-acting (LA) cabotegravir/rilpivirine (CAB/RPV) is primarily prescribed for virologically suppressed persons living with HIV (PLWH). Patients experiencing pill dysphagia or profound adherence challenges were excluded from the phase 3 studies, but recent reports demonstrate successful treatment in PWLH with baseline viremia. We describe two PLWH with detectable viral loads (VL) with multidrug resistance mutations. They were unable to sustain virologic suppression on oral therapy with historical poor adherence and dysphagia. Initiation of intramuscular CAB/RPV with subcutaneous lenacapavir (LEN) injections was necessary with baseline resistance. Due to anorexia and a low muscle mass, one patient received CAB/RPV injections in the vastus lateralis rather than the gluteal muscle with a 67-day delay between injections three and four due to health challenges. Both achieved viral suppression on monthly CAB/RPV with LEN. A return to health with a BMI increase from <14 kg/m2 to almost 17 kg/m2 resulted in the second patient. Injectable LA ART (CAB/RPV + LEN) in PLWH with detectable viremia results in sustained virologic suppression and a return to health and should now be considered a novel option for MDR patients with an inability to adhere to oral regimens.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624241288293"},"PeriodicalIF":1.4,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of concurrent HIV-infection on women with vulvar cancer: Comparison of clinical characteristics and outcome. 同时感染艾滋病毒对女性外阴癌患者的影响：比较临床特征和结果。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-10-03 DOI: 10.1177/09564624241287260

Jennifer L Butt, Judith S Jacobsen, Hannah M Simonds, Matthys H Botha

{"title":"The impact of concurrent HIV-infection on women with vulvar cancer: Comparison of clinical characteristics and outcome.","authors":"Jennifer L Butt, Judith S Jacobsen, Hannah M Simonds, Matthys H Botha","doi":"10.1177/09564624241287260","DOIUrl":"https://doi.org/10.1177/09564624241287260","url":null,"abstract":"Background: HPV-related vulvar cancer is increasing in prevalence, especially in women living with HIV. Treatment of vulva cancer is based on evidence from HPV-independent cancers, which affect older women. The impact of HIV on vulvar cancer characteristics and treatment outcomes needs to be elucidated.Patients and methods: A retrospective observational study compared the clinical characteristics, treatment, and outcomes of 92 HIV-positive and 131 HIV-negative women with vulvar cancer at our institution. Using descriptive statistics, HIV-positive and negative patients were compared and Cox regression models were tested for differences in mortality and recurrence.Results: HIV-positive patients were 20 years younger than HIV-negative patients (p < 0.001). More than 50% of patients presented with advanced stage cancer, however this was independent of HIV-status. Although HIV infection was associated with poorer survival (p = 0.022); rates of cure (p = 0.933) and recurrence rates (p = 0.8) were similar in HIV-positive and negative women.Conclusions: Vulvar cancer occurs at a much younger age in women living with HIV. Awareness among HIV-positive women and health care providers would lead to diagnosis of vulvar cancer at an earlier stage. Treatment protocols for HPV-related vulvar cancer should not be altered due to HIV status and should take into consideration the young age of the patients.","PeriodicalId":14408,"journal":{"name":"International Journal of STD & AIDS","volume":" ","pages":"9564624241287260"},"PeriodicalIF":1.4,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Miliary Pneumocystis jiroveci pneumonia in a patient living with HIV. 一名艾滋病病毒感染者的纤毛膜肺孢子菌肺炎。

IF 1.4 4区医学

International Journal of STD & AIDS Pub Date : 2024-10-01 Epub Date: 2024-08-13 DOI: 10.1177/09564624241273846

Yasemin Çakır Kıymaz, Seyit Ali Büyüktuna

引用次数: 0